Akèy › Limfòm Non-Hodgkin › Utah › Salt Lake City
Etid klinik pou Limfòm Non-Hodgkin nan Salt Lake City, UT
13 etid pou Limfòm Non-Hodgkin ap chèche patisipan nan sit nan ak bò kote Salt Lake City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Ap rekriteFaz 1/2
- Intermountain Health, Canyons Region, LDS Hospital, Salt Lake City
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Ap rekriteFaz 2
- Intermountain Healthcare, Salt Lake City
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
- Intermountain Healthcare, Salt Lake City
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Ap rekriteFaz 1/2
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Ap rekriteFaz 3
- Intermountain Healthcare, Salt Lake City
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- University of Utah, Salt Lake City
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Ap rekriteFaz 1
- University of Utah, Salt Lake City
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Ap rekriteFaz 1/2
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Ap rekriteEtid obsèvasyon
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Ap rekriteFaz 1/2
- University of Utah, Salt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Salt Lake City
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Ap rekriteEtid obsèvasyon
- University of Utah Hospital, Salt Lake City
Etid Limfòm Non-Hodgkin nan lòt vil
- New York City, NY31 etid
- Houston, TX31 etid
- Boston, MA26 etid
- Nashville, TN21 etid
- Philadelphia, PA20 etid
- Baldwin Park, CA19 etid
- Washington, DC18 etid
- Chicago, IL18 etid
- Milwaukee, WI18 etid
- Atlanta, GA18 etid
- Columbus, OH18 etid
- Dallas, TX17 etid
Lòt etid nan Salt Lake City
- Kansè Poumon ki pa ti selil31 etid
- Kansè (tout kalite)27 etid
- Kansè nan tete27 etid
- Kansè kolorektal22 etid
- Kansè poumon21 etid
- Melanom21 etid
- Myelom Miltip21 etid
- Kansè Metastatik20 etid
- Kansè ovè19 etid
- Obèsite18 etid
- Leksemi mieloïd egi17 etid
- Ensifizyans kadyak17 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.